Xvivo Perfusion AB (publ)

OTCPK:XVIP.F Stock Report

Market Cap: US$1.2b

Xvivo Perfusion Valuation

Is XVIP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XVIP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$49.16
Fair Value
20.7% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: XVIP.F ($39) is trading below our estimate of fair value ($49.16)

Significantly Below Fair Value: XVIP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIP.F?

Key metric: As XVIP.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for XVIP.F. This is calculated by dividing XVIP.F's market cap by their current earnings.
What is XVIP.F's PE Ratio?
PE Ratio65.5x
EarningsSEK 204.27m
Market CapSEK 13.37b

Price to Earnings Ratio vs Peers

How does XVIP.F's PE Ratio compare to its peers?

The above table shows the PE ratio for XVIP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.2x
STAA STAAR Surgical
54.2x34.5%US$1.1b
UFPT UFP Technologies
37.2x16.8%US$2.1b
EMBC Embecta
14.2x29.3%US$1.1b
AVNS Avanos Medical
31.4xn/aUS$684.5m
XVIP.F Xvivo Perfusion
65.5x22.1%US$13.4b

Price-To-Earnings vs Peers: XVIP.F is expensive based on its Price-To-Earnings Ratio (65.5x) compared to the peer average (34.2x).

Price to Earnings Ratio vs Industry

How does XVIP.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.8xn/aUS$7.91m
PAVM PAVmed
0.5x-90.0%US$6.48m
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
XVIP.F 65.5xIndustry Avg. 35.9xNo. of Companies6PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: XVIP.F is expensive based on its Price-To-Earnings Ratio (65.5x) compared to the US Medical Equipment industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is XVIP.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIP.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio65.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate XVIP.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$39.00
US$46.99
+20.5%
7.5%US$50.72US$42.94n/a6
Jan ’26n/a
US$49.02
0%
7.8%US$53.20US$43.72n/a6
Dec ’25US$42.90
US$48.97
+14.2%
7.8%US$53.14US$43.68n/a6
Nov ’25US$42.00
US$51.36
+22.3%
6.3%US$54.97US$45.18n/a6
Oct ’25US$48.94
US$51.39
+5.0%
6.6%US$54.67US$44.93n/a6
Sep ’25US$51.16
US$51.39
+0.5%
6.6%US$54.67US$44.93n/a6
Aug ’25n/a
US$51.39
0%
6.6%US$54.67US$44.93n/a6
Jul ’25n/a
US$42.16
0%
13.9%US$49.83US$32.58n/a6
Jun ’25US$41.77
US$37.48
-10.3%
12.0%US$42.99US$31.23n/a6
May ’25US$32.20
US$37.48
+16.4%
12.0%US$42.99US$31.23n/a6
Apr ’25US$26.38
US$36.37
+37.9%
9.0%US$40.40US$32.32n/a5
Mar ’25US$26.22
US$36.37
+38.7%
9.0%US$40.40US$32.32n/a5
Feb ’25US$27.70
US$37.45
+35.2%
7.8%US$40.85US$32.68n/a5
Jan ’25n/a
US$36.98
0%
16.3%US$44.14US$27.46n/a5
Dec ’24n/a
US$33.54
0%
17.1%US$41.50US$25.82US$42.904
Nov ’24US$19.90
US$33.35
+67.6%
18.8%US$40.38US$25.13US$42.003
Oct ’24n/a
US$36.10
0%
11.5%US$41.48US$31.34US$48.943
Sep ’24US$26.43
US$36.10
+36.6%
11.5%US$41.48US$31.34US$51.163
Aug ’24n/a
US$36.56
0%
7.2%US$39.31US$33.00n/a3
Jul ’24n/a
US$36.56
0%
7.2%US$39.31US$33.00n/a3
Jun ’24US$25.35
US$36.56
+44.2%
7.2%US$39.31US$33.00US$41.773
May ’24US$27.51
US$35.86
+30.4%
7.2%US$39.25US$32.95US$32.203
Apr ’24n/a
US$34.11
0%
8.7%US$37.09US$30.06US$26.383
Mar ’24n/a
US$35.38
0%
9.1%US$38.72US$30.20US$26.224
Feb ’24n/a
US$35.38
0%
9.1%US$38.72US$30.20US$27.704
Jan ’24n/a
US$34.19
0%
11.3%US$38.25US$27.83n/a4
Analyst Price Target
Consensus Narrative from 6 Analysts
US$48.26
Fair Value
19.2% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 06:48
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB